News All of Ferrer’s information, just a click away Home News normal Apply We Receive FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP) . Tue, 06/17/2025 - 07:06 We enter into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine . Mon, 04/28/2025 - 09:38 Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management . Wed, 04/23/2025 - 10:23 We are the highest-rated pharma B Corp in the world . Thu, 02/20/2025 - 17:03 Ferrer is recognized for its best-in-class ethics and compliance program . Thu, 01/30/2025 - 07:44 We spearhead two European studies that highlight the urgency of patients and experts to improve the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease . Wed, 11/20/2024 - 08:49 Ferrer advances research into Progressive Supranuclear Palsy (PSP) with the inclusion of the first participant in a Phase II clinical trial . Thu, 08/08/2024 - 08:36 Discover our 2023 Sustainability Report . Wed, 07/10/2024 - 09:48 Ferrer obtains the distribution rights of a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) . Fri, 05/24/2024 - 09:34 People living with pulmonary hypertension call for better psychological support in the absence of awareness of this severe disease . Sun, 04/21/2024 - 21:13 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
We Receive FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP) . Tue, 06/17/2025 - 07:06
We enter into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine . Mon, 04/28/2025 - 09:38
Experts Set International and Multidisciplinary Collaboration As Priorities in Pulmonary Hypertension Management . Wed, 04/23/2025 - 10:23
We spearhead two European studies that highlight the urgency of patients and experts to improve the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease . Wed, 11/20/2024 - 08:49
Ferrer advances research into Progressive Supranuclear Palsy (PSP) with the inclusion of the first participant in a Phase II clinical trial . Thu, 08/08/2024 - 08:36
Ferrer obtains the distribution rights of a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) . Fri, 05/24/2024 - 09:34
People living with pulmonary hypertension call for better psychological support in the absence of awareness of this severe disease . Sun, 04/21/2024 - 21:13